Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
36%
Ph phase_4
1
9%
Ph phase_1
1
9%
Ph phase_3
3
27%
Ph not_applicable
1
9%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(4)
Terminated(1)
Other(6)

Detailed Status

unknown6
Completed4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 24 (40.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

withdrawn19%
completed436%
unknown655%

Recent Activity

0 active trials
Showing 5 of 11
withdrawnphase_2

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

NCT05465902
completednot_applicable

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

NCT06381843
completedphase_2

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

NCT05463354
unknownphase_2

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

NCT06113731
unknownphase_1

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

NCT06113744
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05465902Phase 2

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

Withdrawn
NCT06381843Not Applicable

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

Completed
NCT05463354Phase 2

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

Completed
NCT06113731Phase 2

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Unknown
NCT06113744Phase 1

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Unknown
NCT05374954Phase 3

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above

Unknown
NCT05382871Phase 3

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

Unknown
NCT05323435Phase 2

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

Completed
NCT05367895

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

Unknown
NCT05433272Phase 3

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

Unknown
NCT05398926Phase 4

Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11